Outcome of albendazole therapy in the management of hepatic hydatid disease
DOI:
https://doi.org/10.18203/2320-6012.ijrms20162328Keywords:
Albendazole, Hydatid cyst, Protoscoleces, Viability, RecurrenceAbstract
Background: The treatment modalities for managing patients with hepatic hydatidosis include surgical treatment and non-surgical treatments. The non-surgical methods include albendazole therapy and percutaneous management. Use of albendazole as an adjuvant therapy to surgery has been found to significantly reduce the viability of daughter cyst and recurrence of hydatid disease. The aim of the study was to understand the effect of albendazole therapy on the viability of protoscoleces and recurrence rate of hydatid disease of liver.
Methods: The study was conducted at Sher-i-Kashmir Institute of Medical Sciences and Medical College, Srinagar, Kashmir India, from March 2010 to February 2012 with further follow up of 3-4 years and the total of 64 patients were studied. ; Patients were divided into two groups, Group A and Group B, each comprising of 32 patients. In group A, patients were given albendazole for 12 weeks preoperatively followed by further postoperative course for 12 weeks. In group B, patients were first taken for surgery followed by postoperative course of albendazole for 12 weeks. The two main outcome measures studied and compared during present study were the viability of the hydatid cysts and the recurrence rate in two groups.
Results: Out of those, patients who received preoperative albendazole, 9.37% had viable cysts at the time of surgery as compared to 96.87% of patients who did not receive any preoperative albendazole. In those patients who received only postoperative albendazole therapy, recurrence rate was 18.75% while as there was no recurrence was in patients who received both preoperative and postoperative albendazole therapy.
Conclusions: Study concludes that albendazole is safe and effective adjuvant therapy in the treatment of hydatid liver disease.
Metrics
References
Lewall DB. Hydatid disease. Biology, imaging and classification. Clin Radiol. 1988;53:863-74.
Jenkins DJ. Hydatidosis: A zoonosis of unrecognized increasing importance. J Med Microbial. 1993;31:3211-5.
3. Sherlock S. Hydatid disease: Disease of liver and biliary system. Oxford: Blackwell Scientific Publications, 1981; 247-452.
Barmes Sa, Littlemoe KD. Liver abscess and hydatid cyst disease. Maingot’s abdominal operations 10th ed. 1513-45.
Zargar SA, Khuroo MS, Khan BA, Dar MY. Intra-biliary rupture of hydatid cyst: Sonographic and cholangio-graphic appearances. Gastrointest Radiology. 1992;17:41-5.
Milicevic MN. Hydatid disease: Surgery of liver and biliary tract (L.H. Blumgart & Y. Fong) 3rd edition, W. B. Saunders Company Ltd; London 2000.
Morris DL, Gould SE. Serum and cyst concentrations of mebendazole and flubendazole in hydatid disease. Br Med J of Clinical Research, Edinburg. 1982;285:175.
Morris DL, Chinnery JB et al. Penetration of albendazole sulphoxide into hydatid cyst. Gut 1987;28:75-80.
Teggi A, Lastilla MG, DeRossa F. Therapy of human hydatid disease with mebendazole and albendazole. Antimicrob Ag Chemotherapy 1993;37:1679-84.
Malik AA, Bari SUL, Amin R, Jan M. Surgical management of complicated hydatid cysts of the liver. World J Gastrointest Surg 2010;2(2).
Khuroo MS, Dar MY, Yattoo GN, Zargar SA, Javaid G, Khan BA, et al. Percutaneous drainge versus albendazole therapy in hepatic hydatidosis: a prospective randomized study. Gastroenterology. 1993;104:1452-59.
Khuroo MS. Hydatid disease: Current status and recent advances. Annals of Saudi Medicine 2002;22:56-64.
Bari SUL, Arif SH, Malik AA, Khawja AR, Dass T A, Naikoo ZA. Role of Albendazole in the Management of Hydatid Cyst Liver The Saudi Journal of Gastroenterology. 2011;17(5):343-7.
Morris DL. Preoperative albendazole therapy for hydatid cyst. Br J Surgery. 1987;74:805-06.
Horton RJ. Chemotherapy of Echinococcus infection in man with albendazole. Trans of Roy Soc of Trop Med and Hyg. 1989;83:97-102.
Mottaghian H, Saidi F. Postoperative recurrence of hydatid disease. Br J Surgery. 1978;65:37-42.
Little JM, Hollands MT, Eckberg H. Recurrence of hydatid disease. World J of Surg. 1988;12:700-4.
Morris DL. Albendazole treatment of hydatid disease - followup at 5 years. Tropical Doctor 1989;19:179-180.
Evangelos C. Perioperative benzimidazole therapy in human hydatid liver disease. Int. Surg. 1995;80:131-3.
Downloads
Published
How to Cite
Issue
Section
